Document is current
Any future updates will be listed below
-
Authors
Klarqvist, Marcus D. R. https://orcid.org/0000-0001-7630-2708
Agrawal, Saaket https://orcid.org/0000-0002-2535-4759
Diamant, Nathaniel https://orcid.org/0000-0002-1738-304X
Ellinor, Patrick T.
Philippakis, Anthony
Ng, Kenney
Batra, Puneet https://orcid.org/0000-0001-6822-0593
Khera, Amit V. https://orcid.org/0000-0001-6535-5839
-
Funding
Funding for this research was provided by:
Sarnoff Cardiovascular Research Foundation
IBM Research
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1K08HG010155, 1U01HG011719)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 6 July 2022
First Online: 27 July 2022
Competing interests
: The authors declare no competing non-financial interests, but the following competing financial interests: M.D.R.K., N.D., A.P., and P.B. are supported by grants from Bayer AG applying machine learning in cardiovascular disease. S.A. has served as a scientific consultant to Third Rock Ventures. P.T.E. receives sponsored research support from Bayer AG and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. A.P. is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. K.N. is an employee of IBM Research. P.B serves as a consultant for Novartis. A.V.K. is an employee and holds equity in Verve Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from IBM Research.
